Vertex Pharmaceuticals

CRISPR therapy shows promise in children as young as 5 with sickle cell disease

HCA Healthcare announced on Monday that research published in The New England Journal of Medicine demonstrates promising results from a CRISPR gene-editing therapy tested in children ages 5 to 11 with severe sickle cell disease and transfusion-dependent beta thalassemia, marking…